This observational study will follow patients requiring implantation of leadless pacemaker for 5 years after implantation. The main goal is to evaluate the long term safety and efficacy of AVEIR™ leadless pacemaker device in the usual clinical settings within the UK National Health Service. In addition, the study will collect data to understand patient characteristics receiving this type of pacemaker.
AVEIR™ stimulator (Abbott) obtained the approvals in July 2023 and started to be implanted in patients in Europe. As a leadless pacemaker, the AVEIR™ Leadless Pacemaker (LP) does not need a connector, pacing lead, or pulse generator pocket. The LP is delivered percutaneously via the femoral vein through an AVEIR™ Introducer and Delivery Catheter. AVEIR™ LP is intended to provide bradycardia pacing as a pulse generator with built-in battery and electrodes for implantation. The LP is intended to provide sensing of intrinsic cardiac signals and delivery of cardiac pacing therapy to the target treatment group. The purpose of this study is to understand long term safety and performance characteristic of this device. In addition, the study will collect anonymous clinical data and characteristics of the patients chosen to be implanted with AVEIR™ leadless pacemaker in routine clinical practice in approved centres across the UK. Six hundred patients will be recruited in up to 15 centres during 2 years recruitment period. They will be followed up for 5 years after implantation of the leadless pacemaker. Investigators will record their age, sex, medical history, indications for receiving AVEIR™ and any complications related to the implantation procedure or the device itself. All the data will be collected in an anonymous format. Patients will be followed up according to the standard of care in the national health care system.
Study Type
OBSERVATIONAL
Enrollment
300
AVEIR™ leadless pacemaker implantation
Royal Brompton Hospital
London, UK, United Kingdom
RECRUITINGThe Royal Brompton Hospital
London, United Kingdom
NOT_YET_RECRUITINGPercentage of patients without complications related to the device or implantation procedure.
Complications arising from the procedure or the device will be recorded to evaluate the success rate of the implantation.
Time frame: 5 years
Percentage of patients requiring re-intervention.
Replacement, explant, upgrade, or modification of the position of the device are considered re-interventions which will be used to evaluate safety of the device.
Time frame: 5 years
Stimulation threshold (V) in the therapeutic zone
Minimum current needed to stimulate the paced chamber.
Time frame: 5 years
Percentage of stimulation in the therapeutic zone
Percentage of paced vs non paced heart beats.
Time frame: 5 years
Impedance (Ohm) of R waves in the therapeutic zone
Physiological measure recorded by the device.
Time frame: 5 years
Amplitudes of R waves (mV) in the therapeutic zone
Physiological measure recorded by the device.
Time frame: 5 years
Age of patient (years) at AVEIR ™ leadless pacemaker implantation
Collected as part of the demographics data for the patient group under investigation.
Time frame: 5 years
Sex of patient at AVEIR ™ leadless pacemaker implantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Collected as part of the demographics data for the patient group under investigation.
Time frame: 5 years
Medical history at AVEIR ™ leadless pacemaker implantation
List of significant cardiac or other comorbidities at the time of pacemaker implantation to describe patient population receiving AVEIR ™ leadless pacemaker.
Time frame: 5 years
Indications for AVEIR ™ leadless pacemaker implantation
Collected as part of the demographics data for the patient group under investigation.
Time frame: 5 years